<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862733</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1100</article-id><article-id pub-id-type="other">EPV0376</article-id><article-id pub-id-type="pii">S0924933824011003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>&#x0201c;It was all yellow&#x0201d; first patient with resistant depresion treated with esketamina</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mateos - Sexmero</surname><given-names>M. J.</given-names></name><xref rid="aff2486" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Arribas - Sim&#x000f3;n</surname><given-names>B.</given-names></name><xref rid="aff2486" ref-type="aff"/><xref rid="cor0956" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jim&#x000e9;nez - Aparicio</surname><given-names>T.</given-names></name><xref rid="aff2486" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;n - Santiago</surname><given-names>&#x000d3;.</given-names></name><xref rid="aff2486" ref-type="aff"/></contrib></contrib-group><aff id="aff2486">Psychiatry, <institution>Hospital Cl&#x000ed;nico Universitairo de Valladolid</institution>, <city>Valladolid</city>, <country>Spain</country></aff><author-notes><corresp id="cor0956"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1075">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S529</fpage><lpage>S530</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824011003a.pdf"/><abstract><sec id="sec5748"><title>Introduction</title><p>Esketamine, an active Ketamine isomeric form that indirectly inhibits the GABAergic neuronal pathways, has been recently approved to treated severe, resistant depressive disorders.&#x000a0;Here, we present the case of a 64 years old woman diagnosed with severe, resistant depression and an initial score of 28 points in the Hamilton Depression Rating Scale who was treated with Esketamine with excellent response and a HDRS of 8 points after 4 months.</p></sec><sec id="sec5749"><title>Objectives</title><p>To expose our experience with the first patient treated with Esketamine in our Hospital.</p></sec><sec id="sec5750"><title>Methods</title><p>Describing the patient&#x02019;s patobiography and the different treatments lines tried in first place and exposing the experience among Ketamine treatment and the final results.</p></sec><sec id="sec5751"><title>Results</title><p>We present the case of a 64 years old woman, divorced and retired, who lives with her son since the aggravation of the depressive symptomatology, with no medical nor surgical background and no history in Mental Health before her first psychiatric internment in 2020. Between February 2020 and June 2023, 5 different treatments options with supervise intake were tried, including increment of the dose, antidepressant rotation, the combination of Desvenlafaxine + Mirtazapine and adding Topiramate and Lithium, with no improvement. Among this years, 3 psychiatric internments were needed because of the depressive symptoms and 1 more hospitalization in Internal Medicine was required because of the patients severe, malnutritional state. In June 2023 and after two complete analysis, a MR and a score of 28 points in the Hamilton Depression Rating Scale treatment with Esketamine was started with no incidences. She described one dissociative episode during which she assures &#x0201c;she was surrounded by soft, rubbery, yellow bubbles&#x0201d;. After 4 months of treatment the patient has recovered her previous functional rate and has an 8 points score in the HDRS.</p></sec><sec id="sec5752"><title>Conclusions</title><p>In conclusion, we can affirm that Esketamine is an effective and secure option for Resistant Depresion Dissorder. Nevertheless, Before considering a Depressive Episode as &#x0201c;resistant to treatment&#x0201d;, treatment adherence and other medical, surgical and psychiatric comorbidities must be studied.</p></sec><sec id="sec5753"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>